← All companies

PBLS

Parabilis Medicines, Inc.

PBLS Nasdaq Pharmaceutical Preparations EDGAR ↗

$33.96

+1.68 +5.20%

Key statistics

from XBRL data in SEC filings

Market cap

—

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

—

Total assets

—

Gross margin

—

52-week range

$24.51 – $34.93

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement; Unregistered sale of equity; Amended charter or bylaws Jun 11, 2026

Other filings

4 Jul 22, 2026 4 Jun 29, 2026 3 Jun 29, 2026 SCHEDULE 13D Jun 18, 2026 4 Jun 16, 2026 4 Jun 15, 2026 4 Jun 15, 2026 4 Jun 15, 2026 4 Jun 15, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 S-8 Jun 10, 2026 424B4 Jun 10, 2026 FWP Jun 10, 2026 EFFECT Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 3 Jun 9, 2026 S-1MEF Jun 9, 2026 CERT Jun 9, 2026